Study of Tofacitinib In Refractory Dermatomyositis (STIR): An open label pilot study of 10 patients

Study found tofacitinib 11 mg XR daily provided some benefit in ACR/EULAR Myositis Response Criteria total improvement scores and CDASI scores, suggesting efficacy of tofacitinib in dermatomyositis, but future RCTs are required.

Source:

Arthritis & Rheumatology